News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Skyepharma PLC FY Pretax Loss 23.7M STG
March 27, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON (Thomson Financial) - UK drug delivery specialist SkyePharma says that pretax loss for the full year widened to 23.7 mln stg vs 19.3 mln, mainly due to R&D expenses associated with the continuing development of its asthma product Flutiform.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
Earnings
AstraZeneca employs $1.5B cost savings to reinvest back into growth
October 30, 2026
·
3 min read
·
Annalee Armstrong
Earnings
Regeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deck
October 30, 2026
·
4 min read
·
Heather McKenzie
Earnings
Sanofi targets late-phase and commercial M&A to offset looming Dupixent decline
October 30, 2026
·
2 min read
·
Nick Paul Taylor
Earnings
‘We need to do better,’ Alnylam CEO admits, as uncertainty looms over transthyretin franchise
October 30, 2026
·
3 min read
·
Annalee Armstrong
